Eculizumab as first-line treatment for patients with severe presentation of complement factor H antibody–mediated hemolytic uremic syndrome.

Background: Complement factor H (FH) antibody–mediated hemolytic uremic syndrome (HUS) has varying prevalence globally. Plasmapheresis and immunosuppressive drugs are the standard treatment. Recently, eculizumab has been reported as an effective alternative. This study aims to report four children w...

Descripción completa

Detalles Bibliográficos

Publicado en:	Pediatric Nephrology Vol. 40; no. 4; pp. 1041 - 1048
Autores principales:	Coccia, Paula A., Alconcher, Laura F., Ferraris, Veronica, Lucarelli, Lucas I., Grillo, Maria A., Arias, Maria Andrea, Saurit, Mariana, Ratto, Viviana M., dos Santos, Celia, Sánchez-Luceros, Analía
Formato:	case study research tables/charts Journal Article
Publicado:	Springer Nature Apr2025
Acceso en línea:	Ver este registro en EBSCOhost